119 related articles for article (PubMed ID: 20669178)
41. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
42. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
43. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
44. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
45. Update on recent developments for patients with newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
[TBL] [Abstract][Full Text] [Related]
46. Delayed complete remission in a patient with multiple myeloma.
Ria R; Vacca A; Mangialardi G; Dammacco F
Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
[TBL] [Abstract][Full Text] [Related]
47. Treatment of myeloma--are we making progress?
Durie BG
N Engl J Med; 2008 Aug; 359(9):964-6. PubMed ID: 18753654
[No Abstract] [Full Text] [Related]
48. [Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
Mino T; Sakai A; Kinoshita M; Yoshida T; Mihara K; Imagawa J; Kimura A
Rinsho Ketsueki; 2012 Jan; 53(1):92-6. PubMed ID: 22374531
[TBL] [Abstract][Full Text] [Related]
49. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
Capalbo S; Chiefa A; Delia M; Diomede D; Liso V
Acta Oncol; 2007; 46(2):262-4. PubMed ID: 17453381
[No Abstract] [Full Text] [Related]
50. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Tamura S; Koyama A; Shiotani C; Kurihara T; Nishikawa A; Okamoto Y; Fujimoto T
Intern Med; 2014; 53(11):1171-5. PubMed ID: 24881743
[TBL] [Abstract][Full Text] [Related]
51. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2015 Jan; 56(1):232-5. PubMed ID: 24884320
[No Abstract] [Full Text] [Related]
52. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
54. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
55. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
Al-Nawakil C; Tamburini J; Bardet V; Chapuis N; Bourry E; Roux C; Park S; Choquet S; Dreyfus F; Bouscary D
Leuk Lymphoma; 2008 Oct; 49(10):2012-4. PubMed ID: 18720213
[No Abstract] [Full Text] [Related]
56. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
[TBL] [Abstract][Full Text] [Related]
57. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib-induced Sweet's syndrome.
Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
[TBL] [Abstract][Full Text] [Related]
59. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
60. [A case of the successful treatment of acute plasmablastic leukemia].
Rekhtina IG; Shchekochikhin SM
Ter Arkh; 1997; 69(11):70-1. PubMed ID: 9483754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]